Anzeige
Mehr »
Mittwoch, 28.01.2026 - Börsentäglich über 12.000 News
1 Billion Dollar reichen nicht: Europas kritisches Rohstoffproblem
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
218 Leser
Artikel bewerten:
(0)

Nektium Pharma Commended by Frost & Sullivan for Introducing Zynamite, a Novel Natural Extract with Ergogenic and Nootropic Properties

The product is a caffeine alternative and offers a range of benefits like superior mental and physical performance

LONDON, May 21, 2019 /PRNewswire/ -- Based on its recent analysis of the European sports nutrition and health ingredients market, Frost & Sullivan recognises Spain-based Nektium Pharma with the 2019 European New Product Innovation Award for its novel natural botanical extract, Zynamite. This product has demonstrated significant ergogenic and nootropic properties including faster reaction time and better mental and physical performance. It is a safe and sustainable alternative to caffeine, with nutritional benefits that are superior to those of competing natural extracts.

Click here to view the full multimedia release: https://best-practices.frost-multimedia-wire.com/nektiumpharma

"Nektium launched the novel, patent-pending Mangifera indica extract, Zynamite, which is derived from mango leaves and composed of 60 percent mangiferin, a xanthone. It has been shown to have ergogenic and nootropic properties that enable early mental activation; better mental and physical performance; and dramatic increases in peak power, mean power output, VO2 max, muscle oxygen utilisation, and brain oxygenation. It is also an inhibitor of catechol-O-methyltransferase, or COMT, which has anti-addictive potential," said Smriti Sharma, industry analyst. "While other companies too have developed novel herbal or plant-based nootropic agents, none offer the combination of benefits that Zynamite does."

The company has already conducted four clinical studies on Zynamite and is in the middle of a fifth. Its strong patent portfolio, with three pending patents for different attributes of the mangiferin extract, protects its first-mover advantage. The company showed that the activation mechanism of Zynamite on the central nervous system is different to that of caffeine but with a surprisingly similar effect, which gives it an edge over other key natural extracts. Furthermore, Zynamite has shown no side effects among users. As mango leaves are available year-round, the product meets sustainability and clean label requirements.

Nektium has developed a proprietary technology for concentrating mangiferin and excluding allergens. Its main advantage as an ingredient manufacturer is that its entire operation is conducted under one roof, presenting it with full control over all processes and the freedom to enforce strict quality standards. Its state-of-the-art purification technology limits concentrations of pesticides or other residues and ensures that the relative concentration of bioactive compounds is maintained across different batches.

"Zynamite can be formulated into powders, tablets, chewing gums, gummies, chocolates, and beverages, so potential buyers may find creative application areas for the product," noted Sharma. "Several market giants use Zynamite due to its strong benefits, detailed testing process, and lack of side effects, and the company is expected to sustain this momentum in the future."

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognises the value-added features/benefits of the product and the faster return on investment it gives to the customers, which, in turn, raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Nektium Pharma

Nektium carefully integrates traditional knowledge, nature and science to make outstanding botanical extracts. The innovative botanical ingredients company discovers, develops and commercializes science-based natural ingredients through close integration of the departments of R&D, production and Quality Assurance. Nektium provides seamless research-based solutions to the nutraceutical industry with an ingredient portfolio that includes branded ingredients and standardized extracts.

Contact:

Deborah Thoma
Marketing Manager at Nektium Pharma
P: +34 928734132
E: dthoma@nektium.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:

Samantha Park
P: 210.247.2426
E: samantha.park@frost.com

Photo - https://mma.prnewswire.com/media/889142/Nektium_Award.jpg

© 2019 PR Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.